These novel findings in our experiments enrich the candidate drug targets of EGCG, indicating that the application of EGCG might be a plausible strategy for the treatment of degenerative diseases related to the circadian clock disorders, such as IDD. This evidence concerns the gene CLOCK and intervertebral disk degenerative disorder.